After DEN treatment for 8 weeks followed by sorafenib treatment for 12 weeks, we found remarkable pathological changes in the esophagus of control mice, while the lesion area and ESCC numbers were significantly reduced in the Mettl1 cKO mice (Fig. 5a–e). The gene discussed is METTL1; the disease is esophageal squamous cell carcinoma.